 "Biocon's facility. Photo: Company's website")
Biopharmaceuticals major Biocon said on Monday it has appointed Suresh Subramanian as a senior vice-president and head of the company's branded formulations business for India.
The division is focused on the chronic therapy areas such as diabetes, cancer and autoimmune conditions.
Subramanian had played a critical role in mapping the pharma opportunity in India as part of the steering committee for McKinsey's India Pharma 2020 report. Over the last 30 years in the pharmaceutical sector, he has worked with GlaxoSmithKline, Novartis, AstraZeneca and Pfizer.
"Over the years, he has played multiple leadership roles in business development, marketing, sales and strategy," Biocon said in a statement.
"We are extremely delighted to have Suresh Subramanian lead our branded formulations business in India. Subramanian has deep expertise in diverse therapy areas, including oncology, cardiology and critical care and has a proven track record of delivering robust business growth. We are sure, under his leadership, our branded formulations business will evolve further and become a strong value builder for Biocon," said Kiran Mazumdar-Shaw, CMD, Biocon,
Subramanian is a physics graduate and has a masters in marketing management from Mumbai University.
The branded formulation business was the first to manufacture ALZUMAb, the world's first anti-CD6 monoclonal antibody introduced in India for Psoriasis. The company claims that their product Insugen is the largest Indian Insulins brand and Basalog is a leading Indian Insulin Glargine brand.
